Adaptive Biotechnologies Corporation (ADPT) Earnings History
Annual and quarterly earnings data from 2017 to 2024
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 59.7% | -90.8% | -89.1% |
| 2023 | 55.6% | -133.3% | -132.3% |
| 2022 | 68.7% | -108.0% | -108.0% |
| 2021 | 68.1% | -135.4% | -134.3% |
| 2020 | 77.1% | -155.3% | -148.6% |
Download Data
Export ADPT earnings history in CSV or JSON format
Free sign-in required to download data
Adaptive Biotechnologies Corporation (ADPT) Earnings Overview
As of March 5, 2026, Adaptive Biotechnologies Corporation (ADPT) reported trailing twelve-month net income of -$80M, reflecting +0.3% year-over-year growth. The company earned $-0.49 per diluted share over the past four quarters, with a net profit margin of -0.9%.
Looking at the long-term picture, ADPT's historical earnings data spans multiple years. The company achieved its highest annual net income of -$43M in fiscal 2017.
Adaptive Biotechnologies Corporation is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to industry peers including CAI (-$538M net income, -0.7% margin), VCYT ($66M net income, 0.1% margin), NAUT (-$63M net income), ADPT has room to improve margins relative to the peer group. Compare ADPT vs CAI →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$159M | +29.2% | -$163M | $-1.08 | -89.1% | -90.8% |
| 2023 | -$225M | -12.5% | -$227M | $-1.56 | -132.3% | -133.3% |
| 2022 | -$200M | +3.4% | -$200M | $-1.00 | -108.0% | -108.0% |
| 2021 | -$207M | -41.8% | -$209M | $-1.46 | -134.3% | -135.4% |
| 2020 | -$146M | -113.1% | -$153M | $-1.06 | -148.6% | -155.3% |
| 2019 | -$69M | -47.7% | -$78M | $-0.47 | -80.6% | -92.1% |
| 2018 | -$46M | -8.4% | -$50M | $-0.44 | -83.4% | -89.4% |
| 2017 | -$43M | - | -$44M | $-0.41 | -111.4% | -115.7% |
See ADPT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ADPT Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare ADPT vs LLY
See how ADPT stacks up against sector leader Eli Lilly and Company.
Start ComparisonFrequently Asked Questions
Is ADPT growing earnings?
ADPT EPS of $-0.49 reflects slowing growth at +0.3%, below the 5-year CAGR of N/A. TTM net income is $-80M. Expansion rate has moderated.
What are ADPT's profit margins?
Adaptive Biotechnologies Corporation net margin is -0.9%, with operating margin at -0.9%. Below-average margins reflect competitive or cost pressures.
How consistent are ADPT's earnings?
ADPT earnings data spans 2017-2024. The current earnings trend is +0.3% YoY. Historical data enables comparison across business cycles.